[Clinical practice guidelines from the Andalusian Society of Infectious Diseases (SAEI) for the treatment of tuberculosis]
| Autor: | Angel, Domínguez-Castellano, Alfonso, Del Arco, Jesús, Canueto-Quintero, Antonio, Rivero-Román, José María, Kindelán, Ricardo, Creagh, Felipe, Díez-García |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Adult
Male Salvage Therapy Clinical Trials as Topic Evidence-Based Medicine Antitubercular Agents Disease Management HIV Infections Comorbidity Emigration and Immigration Drug Administration Schedule Treatment Refusal Organ Specificity Pregnancy Tuberculosis Multidrug-Resistant Humans Tuberculosis Drug Therapy Combination Female Pregnancy Complications Infectious Child |
| Zdroj: | Enfermedades infecciosas y microbiologia clinica. 25(8) |
| ISSN: | 0213-005X |
| Popis: | The therapeutic scheme for initial pulmonary tuberculosis recommended by the SAEI is as follows: Initial phase, isoniazid, rifampin and pyrazinamide given daily for 2 months. In HIV(+) patients and immigrants from areas with a rate of primary resistance to isoniazid4%, ethambutol should be added until susceptibility studies are available. Second phase (continuation phase): rifampin and isoniazid, given daily or intermittently for 4 months in the general population. HIV(+) patients (or = 200 CD4) and culture-positive patients after 2 months of treatment should receive a 7-month continuation phase. A 6-month regimen is recommended for extrapulmonary tuberculosis, with the exception of tuberculous meningitis, which should be treated for a minimum of 12 months and bone/joint tuberculosis, treated for a minimum of 9 months. Treatment regimens for multidrug resistant tuberculosis are based on expert opinion. These would include a combination of still-useful first-line drugs, injectable agents, and alternative agents, such as quinolones. Patients who present a special risk of transmitting the disease or of non-adherence should be treated with directly observed therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|